Update on Treatment of Type 1 Diabetes in Childhood

Current Pediatrics Reports

Volumn 1, Issue 2, 2013, Pages 118-127

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

C peptide; Closed loop; GAD; Immune intervention; Monoclonal antibodies; Type 1 diabetes

Indexed keywords

EID: 84963597200     PISSN: None     EISSN: 21674841     Source Type: Journal    
DOI: 10.1007/s40124-013-0012-x     Document Type: Review

References (82)

1. Aanstoot HJ, Anderson BJ, Daneman D, Danne T, Donaghue K, Kaufman F, Réa RR, Uchigata Y. The global burden of youth diabetes: perspectives and potential. Pediatr Diabetes. 2007;8(Suppl 8):1–44.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. DOI: 10.1056/NEJM199309303291401
3. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330:15–8. DOI: 10.1056/NEJM199401063300103
4. Wild D, Von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10–1. DOI: 10.1016/j.pec.2007.05.003
5. • Harjutsalo V, Forsblom C, Groop PH Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ. 2011;343:d5364. This article analyzing a very large amount of patient material in a country with high quality of treatment shows alarming figures for T1D mortality.
6. Danne T, Aman J, Schober E, Deiss D, Jacobsen JL, Friberg HH. Jensen LH; ANA 1200 Study Group A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26(8):2359–64. DOI: 10.2337/diacare.26.8.2359
7. Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr. 2008;153(4):547–53. DOI: 10.1016/j.jpeds.2008.04.063
8. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11(4):372–8. DOI: 10.1111/j.1463-1326.2008.00976.x
9. Danne T, Datz N, Endahl L, Haahr H, Nestoris C, Westergaard L, Fjording MS, Kordonouri O. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008;9(6):554–60. DOI: 10.1111/j.1399-5448.2008.00443.x
10. Deiss D, Kordonouri O, Hartmann R, Hopfenmüller W, Lüpke K, Danne T. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2007;8(3):157–62. DOI: 10.1111/j.1399-5448.2007.00252.x
11. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med. 2007;24(1):27–34. DOI: 10.1111/j.1464-5491.2007.02024.x
12. Herwig J, Scholl-Schilling G, Böhles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab. 2007;20(4):517–25. DOI: 10.1515/JPEM.2007.20.4.517
13. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001;24(2):296–301. DOI: 10.2337/diacare.24.2.296
14. • Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–44. This article was one of the first to point out the possibly increased risk of cancer caused by insulin analogues. Even though other studies have shown different results, it is important to increase awareness of the risks associated with new drugs.
15. Sciacca L, Le Moli R, Vigneri R. Insulin analogs and cancer. Front Endocrinol (Lausanne). 2012;3:21.
16. Kalra S, Baruah MP. Niazi AK Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(1):18–23. DOI: 10.2174/187221412799015326
17. Nordwall M, Ludvigsson J. Use of an insulin pen with memory is not enough to give better glycaemic control. Pediatr Diabetes. 2011;12(Suppl 15).
18. Adolfsson P, Veijola R, Huot C, Hansen HD, Lademann JB, Phillip M. Safety and patient perception of an insulin pen with simple memory function for children and adolescents with type 1 diabetes–the REMIND study. Curr Med Res Opin. 2012;28(9):1455–63. DOI: 10.1185/03007995.2012.698258
19. • Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes. 2009;10(2):142–8. Missed insulin doses are common in treatment of T1D, not least in pump patients. This is a clinically very important finding!
20. Fuld K, Conrad B, Buckingham B, Wilson DM. Insulin pumps in young children. Diabetes Technol Ther. 2010;12(Suppl 1):S67–71.
21. Müller-Godeffroy E, Treichel S, German Working Group for Paediatric Pump Therapy. Investigation of quality of life and family burden issues during insulin pump therapy in children with type 1 diabetes mellitus–a large-scale multicentre pilot study. Diabetes Med. 2009;26(5):493–501. DOI: 10.1111/j.1464-5491.2009.02707.x
22. • Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336–47. This meta-analysis underlines that an insulin pump is very useful, but not the solution.
23. Pickup J. Insulin pumps. Int J Clin Pract Suppl. 2011;170:16–9. DOI: 10.1111/j.1742-1241.2010.02574.x
24. Hanas R, Ludvigsson J. Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. Pediatr Diabetes. 2006;7(Suppl 4):32–8. DOI: 10.1111/j.1399-543X.2006.00169.x
25. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O’Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76. DOI: 10.1056/NEJMoa0805017
26. Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, Shaw JA, Pickup JC, Amiel SA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011;34:2023–5. DOI: 10.2337/dc10-2411
27. • Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, Blasig S, Wadien T, Zierow S, Hartmann R, Thomas A. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther. 2011;13:1–6. A modern technique with improved pumps will fost probably further improve both metabolic control and quality of life.
28. Holl RW, Swift PG, Mortensen HB, Lynggaard H, Hougaard P, Aanstoot HJ, Chiarelli F, Daneman D, Danne T, Dorchy H, Garandeau P, Greene S, Hoey HM, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Sovik O, Tsou RM, Vanelli M, Aman J. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr. 2003;162(1):22–9. DOI: 10.1007/s00431-002-1037-2
29. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 Pt 1):933–8. DOI: 10.1542/peds.111.5.933
30. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA, STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20. DOI: 10.1056/NEJMoa1002853
31. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health. 2012;15(5):632–8. DOI: 10.1016/j.jval.2012.02.011
32. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385–95. DOI: 10.1038/nrendo.2011.32
33. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De PA, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375:743–51. DOI: 10.1016/S0140-6736(09)61998-X
34. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323–9. DOI: 10.1530/eje.0.1490323
35. Rr Enande, Gundevall C, Strömgren A, Chaplin J, Hanas R. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2012;13(7):545–51. DOI: 10.1111/j.1399-5448.2012.00883.x
36. Błazik M, Pańkowska E. The effect of bolus and food calculator Diabetics on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT. Pediatr Diabetes. 2012;13(7):534–9. DOI: 10.1111/j.1399-5448.2012.00876.x
37. • Kordonouri O, Hartmann R, Remus K, Bläsig S, Sadeghian E, Danne T. Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapy. Pediatr Diabetes 2012;13(7):540–4. This article reveals that although carbohydrate counting may be good, it is not always sufficient to obtain good metabolic control and other components of food also have to be considered.
38. •• Swift PG, Skinner TC, de Beaufort CE, Cameron FJ, Aman J, Aanstoot HJ, Castaño L, Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, Mortensen HB, Njølstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M, Ackermann RW, Skovlund SE. Target setting in intensive insulin management is associated with metabolic control: the Hvidoere Childhood Diabetes Study Group Centre Differences Study 2005. Pediatr Diabetes. 2010;11(4):271–8. This is a very important article strongly suggesting that devices or the number of insulin injections alone cannot explain the degree of metabolic control, and perhaps as important is the approach and the goals of the diabetes team.
39. Ludvigsson J. Insulin, love and care. Horm Res. 1989;31:204–9. DOI: 10.1159/000181117
40. Nordfeldt S, Hanberger L, Malm F. Ludvigsson J Development of a PC-based diabetes simulator in collaboration with teenagers with type 1 diabetes. Diabetes Technol Ther. 2007;9(1):17–25. DOI: 10.1089/dia.2006.0053
41. Ekberg J, Ericson L, Timpka T, Eriksson H, Nordfeldt S, Hanberger L, Ludvigsson J. Web 2.0 systems supporting childhood chronic disease management: design guidelines based on information behaviour and social learning theories. J Med Syst. 2010;34(2):107–17. DOI: 10.1007/s10916-008-9222-0
42. Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T, Regeur L. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979;2:1257–9. DOI: 10.1136/bmj.2.6200.1257
43. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26:832–6. DOI: 10.2337/diacare.26.3.832
44. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia. 2007;50(3):503–9. DOI: 10.1007/s00125-006-0559-y
45. Jun HS. Regeneration of pancreatic beta cells. Front Biosci. 2008;13:6170–82. DOI: 10.2741/3145
46. Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev. 2009;25(8):691–3. DOI: 10.1002/dmrr.1035
47. Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed). 1983;286:176–8. DOI: 10.1136/bmj.286.6360.176
48. Dupre J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care. 1988;11(Suppl 1):37–44.
49. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 1985;2:271–6.
50. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O′Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:444–6. DOI: 10.1007/BF00404097
51. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia. 1995;38:848–52. DOI: 10.1007/s001250050362
52. Coutant R, Landais P, Rosilio M, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. 1998;41:1040–6. DOI: 10.1007/s001250051028
53. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev. 2001;17:131–6. DOI: 10.1002/dmrr.176
54. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child. 2001;85:149–54. DOI: 10.1136/adc.85.2.149
55. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–9. DOI: 10.2337/diabetes.54.6.1763
56. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608. DOI: 10.1056/NEJMoa043980
57. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53(4):614–23. DOI: 10.1007/s00125-009-1644-9
58. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS. Type 1 Diabetes TrialNet Anti-CD20 Study Group Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–52. DOI: 10.1056/NEJMoa0904452
59. • Sherry N, Hagopian W, Ludvigsson J, Jain SM et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487–97. Even though this phase III trial failed, it showed that in certain subgroups this type of treatment is efficacious. With better selection of patients this type of treatment may be of value.
60. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001;358(9295):1749–53. DOI: 10.1016/S0140-6736(01)06801-5
61. Abulafia-Lapid R, Gillis D, Yosef O, Atlan H, Cohen IR. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun. 2003;20(4):313–21. DOI: 10.1016/S0896-8411(03)00038-6
62. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev. 2007;23(4):286–91. DOI: 10.1002/dmrr.711
63. Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P, Barkai L, Madácsy L, Oroszlán T, Kovács P, Sütö G, Battelino T, Hosszufalusi N, Jermendy G. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev. 2007;23(4):276–85. DOI: 10.1002/dmrr.707
64. Pozzilli P, Guglielmi C, Maggi D, Carlone A, Buzzetti R, Manfrini S. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes. Curr Pharm Des. 2011;17(29):3224–8.
65. Baekkeskov S, Nielsen JH, Marner H, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature. 1982;298:167–9. DOI: 10.1038/298167a0
66. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151–6. DOI: 10.1038/347151a0
67. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med. 1996;2:1348–53. DOI: 10.1038/nm1296-1348
68. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T cells inhibits ongoing autoimmune diabetes in non-obese diabetic mice. Diabetes. 1998;47:894–9. DOI: 10.2337/diabetes.47.6.894
69. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359(18):1909–20. DOI: 10.1056/NEJMoa0804328
70. Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia. 2011;54(3):634–40. DOI: 10.1007/s00125-010-1988-1
71. • Ludvigsson J, Krisky D, Casas R, Battelino T, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366(5):433–42. This phase III trial failed, but shows that autoantigen treatment may be a useful concept, with an effect in certain subgroups of patients. As the treatment is extremely simple and without treatment-related adverse events, it should be developed further.
72. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378(9788):319–27. DOI: 10.1016/S0140-6736(11)60895-7
73. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, O’Connell PJ, Greenbaum C, Kudva YC, Brayman KL, Aull MJ, Larsen C, Kay TW, Fernandez LA, Vantyghem MC, Bellin M, Shapiro AM. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35(7):1436–45. DOI: 10.2337/dc12-0063
74. Qi Z, Yamamoto C, Imori N, Kinukawa A, Yang KC, Yanai G, Ikenoue E, Shen Y, Shirouzu Y, Hiura A, Inoue K. Sumi S Immunoisolation effect of polyvinyl alcohol (PVA) macroencapsulated islets in type 1 diabetes therapy. Cell Transplant. 2012;21(2–3):525–34. DOI: 10.3727/096368911X605448
75. Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C. Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med. 2012;1(1):59–63. DOI: 10.5966/sctm.2011-0017
76. Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32(12):2251–7. DOI: 10.2337/dc09-0773
77. Dungan KM, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev. 2009;25(6):558–65. DOI: 10.1002/dmrr.999
78. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes; a birth-cohort study. Lancet. 2001;358:1500–3. DOI: 10.1016/S0140-6736(01)06580-1
79. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child. 2008;93:512–7. DOI: 10.1136/adc.2007.128579
80. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler A-G. No effect of the 1α,25-dihydroxyvitamin D3 on β-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care. 2010;33(7):1443–8. DOI: 10.2337/dc09-2297
81. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P, IMDIAB Group. No protective effect of calcitriol on β-cell function in recent-onset type 1 diabetes. The IMDIAB XIII trial. Diabetes Care. 2010;33(9):1962–3. DOI: 10.2337/dc10-0814
82. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial–background and rationale. Diabetes Metab Res Rev. 2009;25(4):321–4.